This article is more than 5 years old. Information may no longer be current.
VIDEO: Venetoclax-rituximab sustains survival benefits in relapsed, refractory CLL at 4 years
ORLANDO — Venetoclax plus rituximab maintained significant improvements in PFS and OS compared with bendamustine plus rituximab 2 years posttreatment among patients with relapsed or refractory chronic lymphocytic leukemia, according to an updated 4-year analysis of the MURANO study presented at the ASH Annual Meeting and Exposition.
In this video, John F. Seymour, MD, director of Peter MacCallum Cancer Centre in Melbourne, Australia, discusses new safety and efficacy data on time-limited therapy with venetoclax (Venclexta; AbbVie, Genentech) plus rituximab (Rituxan; Genentech, Biogen), as well as the outcomes of patients who experienced disease progression posttreatment.
“I think for both patients and clinicians, these updated data should give confidence about the application of the time-limited treatment for the majority of patients in the relapsed/refractory setting,” he told Healio.
Reference:
Seymour JF, et al. Abstract 355. Presented at: ASH Annual Meeting and Exposition; Dec. 7-10, 2019; Orlando.
Disclosure: Seymour reports being a consultant for AbbVie, Acerta, Celgene, Janssen, Roche and Takeda. He also reports receiving research funding from AbbVie, Celgene, Janssen and Roche; speaker’s bureau fees from AbbVie, Celgene and Roche; and honoraria from AbbVie.